We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GRRR:NASDAQGorilla Technology Group Inc. Analysis

Data as of 2026-04-07 - not real-time

$10.84

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Gorilla Technology Group posted a record $101.4 million in revenue for FY2025, a 35.7% year‑over‑year increase, and EPS jumped 91.7% YoY, signaling strong top‑line momentum and improving profitability. However, the company still reports a negative trailing EPS of -$0.51 and operating cash flow remains in the red, while debt‑to‑equity sits at a lofty 7.47, highlighting cash‑flow and leverage concerns. Technically, the stock trades below its 20‑day and 50‑day moving averages, indicating a bearish trend, yet the MACD histogram is positive and RSI hovers near neutral, suggesting short‑term upside potential toward the resistance level of $12.23. With a forward PE of 7.74 versus an industry average of 33.7, the valuation appears significantly undervalued, and analyst price targets imply a potential upside of over 200% from the current $10.84 price.
The high 30‑day volatility (≈75%) and a beta near 1.9 point to pronounced price swings, while stable volume and a modest market cap keep liquidity adequate but not robust. Given the mix of strong revenue growth, an expansive $7 billion pipeline, and substantial valuation discounts, the stock presents a compelling growth‑value case, albeit tempered by cash‑flow deficits, high leverage, and sector‑specific regulatory exposure.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Positive MACD histogram and neutral RSI suggest near‑term bullish momentum
  • Record revenue growth and EPS improvement boost confidence
  • Technical support near $9.04 provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward PE of 7.74 vs industry 33.7 indicates strong valuation upside
  • $7 billion pipeline and continued revenue acceleration
  • Analyst price targets imply >200% upside potential

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Negative operating cash flow and high debt‑to‑equity raise sustainability concerns
  • High volatility and beta increase exposure to market swings
  • Long‑term growth prospects remain attractive if cash‑flow turns positive

Key Metrics & Analysis

Financial Health

Revenue Growth4.80%
Profit Margin-11.13%
P/E Ratio7.7
ROE-8.38%
ROA2.16%
Debt/Equity7.47
P/B Ratio1.4
Op. Cash Flow$-28924084
Free Cash Flow$-17455020
Industry P/E33.7

Technical Analysis

TrendBearish
RSI48.1
Support$9.04
Resistance$12.23
MA 20$10.88
MA 50$11.81
MA 200$15.38
MACDBullish
VolumeStable
Fear & Greed Index76.5

Valuation

Target Price$36.67
Upside/Downside238.25%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.90
Volatility75.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.